13 Quotes by Silke Stegemann

Bayer has now manifest its will to move forward. This is positive because now we know they can stick to their time frame.

If the final price comes in over $40 per share, we would consider this negative.

The pain threshold is around $40. They can't go a lot over $40 without the capital markets seeing that negatively. There is a point where a price would not justify the transaction.

I think Engelhard is opening up to a friendly transaction.

The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit.

Strengthening their product range further down the value chain makes a lot of sense.

This move comes as a surprise, but BASF so far has an excellent track record in acquisitions that were always adding value to investors.

It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it.

This is a good building block for Bayer.